Dexcom Inc (NASDAQ: DXCM), a provider of real-time continuous glucose monitoring (rtCGM) for diabetes patients, declared on Tuesday that it Dexcom G6 CGM System will be available to eligible people of all ages with type 1 and type 2 diabetes in Canadian province Manitoba.
Coverage for rtCGM will be expanded to include all eligible patients with type 1 or type 2 diabetes in Manitoba, which is currently the only province in Canada that does not require an application for preapproval of coverage.
The company said that this positive step ensures that Manitobans are able to improve their self-management of diabetes at home. This is expected to preserve vital health system capacity by reducing the risk of severe hypoglycemia which often results in patients requiring emergency care.
According to Dexcom, use of its rtCGM is proven to improve glycemic control and can reduce the risk of costly long-term diabetes-related complications. The system includes a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device or receiver, giving patients real-time glucose data without the need to scan or prick their finger routinely. Dexcom G6 has customisable and predictive alerts and an urgent low alarm to help avoid potentially dangerous hypoglycemic events. The Dexcom G6 app also allows patients to share their glucose information with up to ten followers.
Saluda Medical secures CE certification for EVA Sensing Technology in Europe
Antin to acquire clinical trial equipment provider Emsere
Hyphens Pharma licenses Cerapro skin cream to Louis Widmer for six European markets
Profusa signs French distributor to expand Lumee Oxygen rollout in Europe
Sensiva Health names new chief operating officer
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
BioCryst wins FDA approval for oral HAE prophylaxis in young children
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Galderma secures EU MDR certification for Sculptra, expanding use to multiple body areas
Clinical Laserthermia Systems applies for CE marking of ClearPoint Prism neuro laser system